Bayer Announces the Grand Opening of its Second Largest OTC Manufacturing Site of Asia-Pacific in Majinpu Yunnan
An investment estimated of CNY 1.4 billion to upgrade the company's TCM productivity, addressing the increasing self-care needs around the world
Kunming, China, January 8, 2016 — Bayer announced a milestone opening of its state-of-the-art manufacturing site of traditional Chinese medicine and western medicine in the Majinpu bioengineering and pharmaceutical industrial park in Yunnan. The site is Bayer's second largest OTC manufacturing facility in Asia Pacific, which will greatly enhance the company's integral capabilities in providing high-quality self-care solutions to meet the diverse healthcare needs of Chinese consumers.
The facility, covering an area of 111,534 square meters, is designed in line with Bayer's global standards for excellence in manufacturing and operations, including an advanced safety and quality control system, and cutting-edge production technologies. The first phase of construction has gained the GMP certificate for its partial TCM production line, the upgrading work is ongoing, which will be put into production for Bayer's key TCM product DEFK.
The construction of Majinpu site was started in 2013 by Dihon, and was taken over by Bayer after the acquisition in November 2014. "With the resolution to promote Dihon's renowned brands for the benefit of a wider population, Bayer keeps exploring the potential of our well-blended advantages." said Celina Chew, President of Bayer Greater China Group. "We are committed to the China market and we will continue to invest in the Life Sciences. Firmly bearing our mission of 'Science For A Better Life', we will deepen our collaborations with local partners, and focus on innovation to provide more advanced healthcare solutions for Chinese people."
"The site consolidates Bayer's TCM supply capabilities in Yunnan. It will boost our manufacturing capacity of TCM products by three times in 2016, and bring about up to triple the manufacturing and supplying capacity for all Dihon products by 2020. The enhanced capacity will enable us to provide high-standard self-care products to more consumers in China and other countries." said Lance Yuen, Head of Greater China, Bayer Consumer Health. "By 2020, the total estimate investment in the facility will amount to CNY 1.4 billion, making the site a full-fledged global hub for Bayer's TCM production and western medicine, further accelerating Bayer's transformation from treating illness to promoting wellness."
"Bayer's manufacturing site in Majinpu is an inspiring model for the strategic development of Yunnan's TCM industry," said Minzheng Wang, Standing Member, Kunming CPC Commission and Chairman of the Administrative Commission of Kunming National Hi-Tech Park "The site brings together Yunnan's rich legacy in TCM and Bayer's global expertise in standardized production, which will open up promising opportunities for Yunnan health industry upgrade with the standardization of quality TCM production. Drawing on the site's capacity and Bayer's global network, we hope Yunnan made TCM products would enter a broader global market."
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2014, the Group employed around 119,000 people and had sales of EUR 42.2 billion. Capital expenditures amounted to EUR 2.5 billion, R&D expenses to EUR 3.6 billion. These figures include those for the high-tech polymers business, which is to be floated on the stock market as Covestro by mid-2016 at the latest. For more information, go to www.bayer.com.
For more information, please contact:
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.